HSDD is more than occasional low libido
*Correspondence: Gerardo Ferrara, [email protected] This article was submitted to Skin Cancer, a section of the journal Frontiers in Oncology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
doi: 10.1016/j.oraloncology.2008.01.014
In laboratory and pre-clinical settings, PT-141 (Bremelanotide) is studied as the defining CNS melanocortin agonist for sexual behaviour neuroscience and melanocortin receptor pharmacology: MC4R pharmacology receptor binding kinetics, Gs/cAMP/PKA signalling, hypothalamic expression mapping, and MC4R-selective research design Melanocortin receptor profiling MC1R/MC3R/MC4R/MC5R binding affinity, SAR studies, and MCR subtype selectivity research Central sexual behaviour neuroscience mPOA and PVN neuronal activation, c-Fos immunoreactivity, and hypothalamic circuit mapping Dopamine system modulation mPOA dopamine release, nucleus accumbens reward integration, and monoaminergic neurotransmitter crosstalk Oxytocin circuit activation PVN oxytocin neuron stimulation and affective/bonding dimension of sexual response HSDD research models female sexual desire deficiency models, melanocortin excitatory pathway engagement, and excitation/inhibition balance Erectile dysfunction research MC4R-mediated erectile pathway, PVN-corpus cavernosum neural connectivity, and PDE5-independent erection modelling CNS vs peripheral mechanism dissection central melanocortin pathway vs nitric oxide/PDE5 axis
Sebaratnam DF, 2024, 'Towards precision medicine in vascular anomalies: Could protein kinase C inhibitors be repurposed for GNAQ/11-related phakomatoses?', Skin Research and Technology , 30, Journal articles | 2024 Gu Y
[40] The excessive production of ETX increases the permeability of the intestines
